Literature DB >> 934223

The stereoselective interaction of warfarin and metronidazole in man.

R A O'Reilly.   

Abstract

Because of the known interaction of warfarin and disulfiram and the "disulfiram effect" of metronidazole, the interaction with metronidazole of commercial racemic warfarin and its separated enantiomorphs was evaluated in eight normal subjects. Single oral doses of racemate, S(-)-warfarin, and R (+)-warfarin, were administered in the amounts of 1.5, 0.75 and 1.5 mg per kilogram of body weight, respectively, with and without metronidazole, 750 mg by mouth, beginning seven days before the warfarin dose and continuing seven days before the warfarin dose and continuing daily throughout the hypoprothrombinemia. Daily plasma samples were analyzed for warfarin in content and one-stage prothrombin time. A highly significant (P less than 0.01) augmentation of the mean warfarin level and hypoprothrombinemia with metronidazole occurred for racemic and S (-)-warfarin; none occurred with R (+)-warfarin. Thus, the interaction of racemic warfarin and metronidazole is stereoselective and can be lessened or even avoided by use of R (+)-warfarin alone for long-term therapy.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 934223     DOI: 10.1056/NEJM197608122950702

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  45 in total

1.  High-risk antimicrobial prescriptions among ambulatory patients on warfarin.

Authors:  M A Lane; S T Devine; J R McDonald
Journal:  J Clin Pharm Ther       Date:  2011-04-24       Impact factor: 2.512

2.  Anti-anaerobic antimicrobial agents: cefoxitin, cefotetan, clindamycin, and metronidazole.

Authors:  J A Bosso; R A Prince
Journal:  Tex Heart Inst J       Date:  1990

Review 3.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

Review 4.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

5.  Serious bleeding events due to warfarin and antibiotic co-prescription in a cohort of veterans.

Authors:  Michael A Lane; Angelique Zeringue; Jay R McDonald
Journal:  Am J Med       Date:  2014-03-19       Impact factor: 4.965

Review 6.  Anticoagulants in older patients. A safety perspective.

Authors:  R J Beyth; C S Landefeld
Journal:  Drugs Aging       Date:  1995-01       Impact factor: 3.923

Review 7.  Clinical pharmacokinetics 1990.

Authors:  G R Matzke; W L St Peter
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

8.  Interaction of clofibrate with warfarin. I. Effect of clofibrate on the disposition of the optical enantiomorphs of warfarin.

Authors:  T D Bjornsson; P J Meffin; T F Blaschke
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

Review 9.  Clinically significant drug interactions with the oral anticoagulants.

Authors:  M D Freedman; A G Olatidoye
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

10.  Enhanced elimination of warfarin during treatment with cholestyramine.

Authors:  E Jähnchen; T Meinertz; H J Gilfrich; F Kersting; U Groth
Journal:  Br J Clin Pharmacol       Date:  1978-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.